ClariTrial | Search Clinical Trials

Phase 3Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

SonlicromanolPlacebo

Khondrion BV220 participants10 sites · United States, Denmark, FranceCompletes Sep 2028

Compare CT.gov Full analysis →

1–15 of 163

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

163 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

Phase 3Muscular Atrophy, Spinal

Salanersen

Biogen30 participants2 sites · United StatesCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy

Phase 2Malignant Brain Neoplasm

Best PracticeMedical Device Usage and EvaluationMetformin+2 more

Mayo Clinic100 participants1 site · United StatesCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease

Phase 1Phase 2Lafora Disease

ION283

Berge Minassian10 participants1 site · United StatesCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

GRAViceptive NEGlect Treatment in Acute Stroke Using Targeted Cranial ELECTrotherapy

Phase 1Phase 2Stroke

Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS)Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS)

University of Sao Paulo28 participants2 sites · BrazilCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Phase 2Parkinson Disease

AP-472Placebo

Appello Pharmaceuticals, Inc.150 participants25 sites · United StatesCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Phase 1Phase 2Multiple SclerosisAlzheimer's Disease

[F-18]PBR06[C-11]PBR28

Brigham and Women's Hospital250 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)

Ocrelizumab (US)Ocrelizumab (EU)ABP 692

Amgen444 participants107 sites · United States, Belgium, BulgariaCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

Phase 1Phase 2Chronic Subdural Hematoma

Bevacizumab 2 mg/kgBevacizumab 4 mg/kg

The Cooper Health System140 participants1 site · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Phase 2Parkinson DiseaseParkinsonIdiopathic Parkinson Disease

NEU-411Placebo

Neuron23 Inc.150 participants70 sites · United States, Israel, ItalyCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Phase 3Ischemic Stroke

Ticagrelor 90 MGCilostazol 100 MGAspirin 75mg+1 more

Kafrelsheikh University900 participants2 sites · EgyptCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Phase 3Migraine

UbrogepantPlacebo for Ubrogepant

AbbVie496 participants106 sites · United States, Puerto RicoCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

Phase 3Lennox Gastaut Syndrome

Clemizole HClPlacebo

Epygenix260 participants20 sites · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD

Phase 2Phase 3Parkinson DiseaseDementia With Lewy BodiesMSA - Multiple System Atrophy

[18F]-MFBG PET CT[18F]-FE-PE2I PET CT or PET MRI[123I]-MIBG SPECT CT+1 more

prof. dr. Koen Van Laere113 participants2 sites · BelgiumCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

Phase 1Phase 2PARKINSON DISEASE (Disorder)ApathySafety

IRL757Placebo

Integrative Research Laboratories AB75 participants13 sites · Bulgaria, Germany, PolandCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

Phase 3Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

SonlicromanolPlacebo

Khondrion BV220 participants10 sites · United States, Denmark, FranceCompletes Sep 2028

Compare CT.gov Full analysis →

1–15 of 163